Package Size Information

Package Size

as of

31-Jan-2025 370 kBq

10 µCi

1.85 MBq

50 µCi

125| Research Reagents

Volume

0.20 ml

1.00 ml

Research use only. Not for use in diagnostic procedures

[¹²⁵I]TyrA¹⁴ Insulin (porcine) [125I]-Receptor Grade Insulin

Product Number: NEX196

LOT SPECIFIC INFORMATION:

CALCULATED AS OF: 23-Dec-2024

LOT NUMBER: CZ13150

SPECIFIC ACTIVITY: 81.4 TBg/mmol

> 2200.0 Ci/mmol 13.7 MBq/µg 371 μCi/μg

CONCENTRATION: 3.2 MBq/ml

86.2 µCi/ml

RADIOCHEMICAL PURITY: MOLECULAR WEIGHT: ≥ 95% ~5.927

PACKAGING: [125] TyrA14 Insulin is in a solution containing 0.05M sodium phosphate, 1M glycine, 0.2M NaCl, 0.25% BSA, 500 KIU/ml Trasylol® at pH 7.2. It is shipped on dry ice.

SPECIAL INFORMATION: This compound is light sensitive. Exposure to light may hasten decomposition. [125] Tyr^{A14} Insulin is supplied in a red NENSURE™ vial which contains a U.V. inhibitor.

STABILITY AND STORAGE: [125] TyrA14 Insulin should be stored at -20°C or lower in the dark. Under these conditions the product is stable and usable for at least four weeks after fresh lot date.

SPECIFIC ACTIVITY: The initial specific activity of [125] TyrA14 Insulin is 2200 Ci/mmol (81 TBq/mmol), 371 μCi/μg

(13.7 MBg/µg). Preparative HPLC is used to separate unlabeled insulin from [125]-TyrA14Insulin. Upon decay, [125] Tyr^{A14}Insulin undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular or peptide fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on 125I decay and decay catastrophe of 125I labeled compounds are available.1-5

RADIOCHEMICAL PURITY: Initially greater than 95% radiochemically pure as determined by HPLC.

POSITION OF LABELING: Limited protease digestion of the product followed by HPLC identification of the fragments⁶ indicates that it is the Tyr^{A14} which is iodinated.

PREPARATIVE PROCEDURE: Porcine insulin is radioiodinated with no carrier added 125 using a modification of the Hunter and Greenwood method7, and is purified by reversed phase HPLC. Only the TyrA14 iodinated isomer is collected as product.

APPLICATIONS: [125] TyrA14 Insulin has been proven to be active in a receptor binding assay using cultured human fibroblasts as described.8 It may also be used in radioimmunoassay.

AVAILABILITY: [125]TyrA14 Insulin is routinely available from stock and prepared fresh and packaged for shipment on the fourth Monday of each month. Please inquire for larger package sizes

HAZARD WARNING: This product contains a chemical (s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion or inhalation. It is irritating to the eyes, skin and respiratory tract. It is toxic and flammable. Target organ is the central nervous system.

RADIATION UNSHIELDED: 280mR/hr/mCi at vial surface.

REFERENCES:

- 1. Doyle, V.M., Buhler, F.R., Burgisser, E., Eur. J. Pharm. 99 353 (1984).
- 2. Schmidt, J., J. Biol. Chem. 259 1660 (1984)
- 3. Loring, R.H., Jones, S.W., Matthews-Bellinger, J., Salpeter, M.M., J. Biol. Chem. 257 1418 (1982).
- 4. Berridge, M.S., Jiang, V.W., Welch, M.J., Radiation Research 82 467 (1980).
- 5. Charlton, D.E., Radiation Research, 107 163 (1986).
- 6. Frank, B., Beckage, M.J. and Willey, K.J., Chrom. 266, 239-248 (1983).
- 7. Hunter, W.M. and Greenwood, F.C., *Nature* <u>194</u>, 495 (1962).
- 8. Podskalny, J. and Kahn, R., J. Clin. Endocrinol. and Metab. 54, 261-268 (1982)

IODINE-125 DECAY CHART HALF LIFE=60 days

Radiations: Gamma 35.5 keV (7%), X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

| DAYS | 0 | 2 | 4 | 6 | 8 | 10 | 12 | 14 | 16 | 18 |
|------|-------|------|------|------|------|------|------|------|------|------|
| 0 | 1.000 | .977 | .955 | .933 | .912 | .891 | .871 | .851 | .831 | .812 |
| 20 | .794 | .776 | .758 | .741 | .724 | .707 | .691 | .675 | .660 | .645 |
| 40 | .630 | .616 | .602 | .588 | .574 | .561 | .548 | .536 | .524 | .512 |
| 60 | .500 | .489 | .477 | .467 | .456 | .445 | .435 | .425 | .416 | .406 |
| 80 | .397 | .388 | .379 | .370 | .362 | .354 | .345 | .338 | .330 | .322 |
| 100 | .315 | .308 | .301 | .294 | .287 | .281 | .274 | .268 | .262 | .256 |
| 120 | .250 | .244 | .239 | .233 | .228 | .223 | .218 | .213 | .208 | .203 |

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.



Revvity, Inc. 940 Winter Street Waltham, MA 02451 USA

(800) 762-4000 www.revvity.com For a complete listing of our global offices, visit www.revvity.com Copyright © 2023, Revvity, Inc. All rights reserved.